U.S., Oct. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07216560) titled 'First-in-human Study of 7MW4911 in GI Cancer' on Sept. 24.
Brief Summary: This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
GI Cancers
Intervention:
DRUG: 7MW4911
study drug
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....